Alterity Therapeutics Limited

NasdaqCM:ATHE Stok Raporu

Piyasa değeri: US$10.5m

Alterity Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Alterity Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9% per year.

Anahtar bilgiler

-2.6%

Kazanç büyüme oranı

31.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı9.0%
Özkaynak getirisi-138.6%
Net Marj-475.8%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

Gelir ve Gider Dağılımı

Alterity Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:ATHE Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 244-19519
31 Mar 244-16515
31 Dec 233-12412
30 Sep 234-13512
30 Jun 234-14513
31 Mar 235-14514
31 Dec 225-14516
30 Sep 225-14515
30 Jun 225-13615
31 Mar 225-13514
31 Dec 215-13713
30 Sep 215-14813
30 Jun 214-15712
31 Mar 212-16711
31 Dec 200-16510
30 Sep 200-15410
30 Jun 200-13310
31 Mar 202-13411
31 Dec 194-13413
30 Sep 195-12413
30 Jun 195-12413
31 Mar 195-11412
31 Dec 184-10410
30 Sep 184-948
30 Jun 183-847
31 Mar 183-845
31 Dec 173-844
30 Sep 173-845
30 Jun 173-846
31 Mar 174-847
31 Dec 164-948
30 Sep 164-849
30 Jun 165-8410
31 Mar 165-8411
31 Dec 156-7512
30 Sep 156-7512
30 Jun 156-6512
31 Mar 158-6613
31 Dec 1410-7313
30 Sep 149-10314
30 Jun 148-13515
31 Mar 146-12313
31 Dec 134-11311

Kaliteli Kazançlar: ATHE is currently unprofitable.

Büyüyen Kar Marjı: ATHE is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ATHE is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

Büyüme Hızlandırma: Unable to compare ATHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ATHE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: ATHE has a negative Return on Equity (-138.6%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin